Bioética, medicamentos, conflicto de intereses y control de calidad
DOI:
https://doi.org/10.18800/derechopucp.201202.012Keywords:
bioethics – drugs – conflict of interest – quality control – risk – access – pharmaceutical sales representatives – therapeutic practiceAbstract
Bioethics, medicines, interests conflict and quality control
The article analyzes the problems of pharmaceutical advertising that distorts, exaggerates or hides certain information (side effects of drugs), as well as the work of pharmaceutical sales representatives, the problem of drugs’ risk, marketing authorization, access to drugs, therapeutic practice, conflicts of interest, and quality control in medicine. These issues have a greater importance in public health; since the lack of respect for the fundamental principles of bioethics (benefit, not harm, autonomy and consent) has a direct impact on the health of the population.
Downloads
References
Bensadon, Anne-Carole & otros (2011). «Enquête sur le Mediator®. Rapport définitif». Inspection générale des affaires sociales RM2011-001P. (http://www.ladocumentationfrancaise.fr/var/storage/rapports-publics/114000028/0000.pdf).1
Bero, Lisa & otros (1992). «The Publication of Sponsored Symposiums in Medical Journals». The New England Journal of Medicine. CCCXXVII , pp. 1135-1140.
Collectif Europe et médicament ( 2003). «Rendre publique la “valeur thérapeutique ajouté des nouveaux médicaments”» (http://www.prescrire.org/docus/valeurAjouteeFr.pdf).
Consumers International (2006). La salud patentada. La perspectiva del consumidor sobre la RSE, la promoción de medicamentos y la industria farmacéutica en Europa. Londres: Consumers International, pp. 10-11 (http://www.consumersinternational.org/media/286105/salud_patentada.pdf).
Consumers International (2007). «La promoción no ética de medicamentos» (http://www.consumidoresint.org/documentos/diamundial/WCRD_briefing_2007_spanish.pdf).
Dana, Jason & George Lowestein (2003). «A Social Science Perspective on Gifts to Physicians from Industry». TheJournal of the American Medical Association, CCXC, 2 , pp. 252-255.
Drews, Jürgen (1998). In Quest of Tomorrow 's Medicines. Nueva York: Sprinter.
Hermange, Marie-Thérèse & Anne-Marie Payet (2006). «Rapport d’information fait au nom de la Commission des affaires sociales sur les conditions de mise sur le marché et de suivi des médicaments» (http://www.senat.fr/rap/r05-382/r05-3820.html).
Katz, Dana & otros (2003). «All Gifts Large and Small: Toward an Understanding of Pharmaceutical Industry Gift-Giving». The American Journal of Bioethics. III, 3 , pp. 39-46.
Krimsky, Sheldon (2003). «Small Gifts, Conflicts of Interest, and the Zero-Tolerance Threshold in Medicine». The American Journal of Bioethics, III, 3 , pp. 50-52.
La rosa, Emilio (2009). La fabricación de nuevas patologías: de la salud a la enfermedad. Lima: FCE.
Le Réseau d’observation de la visite médicale (2005). «La visite médicale trompe toujours énormément». Prescrire, XXV, 259 , p. 191.
Lexchin, Joel (1993). «Interactions between Physicians and the Pharmaceutical Industry: What Does the Literature Say?» Canadian Medical Association Journal, CXLIX, 10, pp. 1401-1407.
LexchiN, Joel (1997). «What Information do Physicians Receive from Pharmaceutical Representatives?». Canadian Family Physician, 43 , pp. 941-945.
Moynihan, Ray (2003). «Who Pays for the Pizza? Redefining the Relationships between Doctors and Drug Companies. 1: Entanglement». BMJ, CCCXXVI, 7400 , pp. 1189-1192.
Norris, Pauline & otros (2004). «Drug Promotion. What We Know, What We Have Yet to Learn. Reviews of Materials in the WHO/HAI Database on Drug Promotion» (http://apps.who.int/medicinedocs/en/d/Js8109e/).
Organisation Mondiale de la Santé (1998). «Critères éthiques applicables à la promotion des médicaments» (http://mednet2.who.int/edmonitor/edition/edm17a.html).
Quick, Jonathan & otros (2003) . «Ensuring Ethical Drug Promotion. Whose Responsibility?». Lancet, CCCLXII, 9385, p. 747.
Rafel Rivera, Josefa & otros (2003). «Valvulopatía cardíaca asociada al uso de benfluorex». Revista Española de Cardiología, LVI, 2 , pp. 215-216.
Smith, IR (2003). «Medical Journals and Pharmaceutical Companies: Uneasy Bedfellows». BMJ, CCCXXVI , pp. 1202-1205.
Thompson, Dennis (1993). «Understanding Financial Conflicts of Interest». The New England Journal of Medicine, CCCXXIX, 8 , pp. 573-576.
Turone, Fabio (2003). «Italian Police Investigate GSK Italy for Bribery». BMJ, CCCXXVI, p. 413.
UNESCO (2005). Declaración Universal sobre Bioética y Derechos Humanos (http://unesdoc.unesco.org/images/0014/001461/146180s.pdf).
Wazana, Ashley (2000). «Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?». Journal of the American Medical Association, CCLXXXIII, 3 , pp. 373-380.
WHO, Clinical pharmacological evaluation in drug control, Copenhagen, WHO, 1993 (EUR/ICP/DSE 173).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Derecho PUCP
This work is licensed under a Creative Commons Attribution 4.0 International License.
